Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features: A Randomized, Double-Blind, Placebo-Controlled Study

Depressive Disorder ◽

Controlled Study ◽

Major Depressive ◽

Double Blind ◽

Double Blind Placebo ◽

Mixed Features

Statement of Retraction: Efficacy and safety of vortioxetine for the treatment of major depressive disorder: a randomised double-blind placebo-controlled study

International Journal of Psychiatry in Clinical Practice ◽

10.1080/13651501.2021.1950437 ◽

2021 ◽

pp. 1-1

Keyword(s):

Depressive Disorder ◽

Controlled Study ◽

Efficacy And Safety ◽

Major Depressive ◽

Double Blind ◽

Factors impacting the efficacy of venlafaxine extended release 75–225 mg/day in patients with major depressive disorder: exploratory post hoc subgroup analyses of a randomized, double-blind, placebo-controlled study in Japan

Neuropsychiatric Disease and Treatment ◽

10.2147/ndt.s146428 ◽

2018 ◽

Vol Volume 14 ◽

pp. 1261-1272 ◽

Author(s):

Yoshinori Watanabe ◽

Yuko Asami ◽

Yoko Hirano ◽

Kazuhiko Kuribayashi ◽

Rio Itamura ◽

...

Keyword(s):

Depressive Disorder ◽

Extended Release ◽

Controlled Study ◽

Major Depressive ◽

Double Blind ◽

Double Blind Placebo ◽

Subgroup Analyses ◽

Post Hoc

Reboxetine, placebo and paroxetine comparison in patients with major depressive disorder: A double-blind, placebo- and comparator-controlled study

European Neuropsychopharmacology ◽

10.1016/s0924-977x(01)80204-2 ◽

2001 ◽

Vol 11 ◽

pp. S216 ◽

Author(s):

C.C. Gallen ◽

M.T. Brown

Keyword(s):

Depressive Disorder ◽

Controlled Study ◽

Major Depressive ◽

Double Blind ◽

Efficacy and safety of vortioxetine for the treatment of major depressive disorder: a randomised double-blind placebo-controlled study

International Journal of Psychiatry in Clinical Practice ◽

10.1080/13651501.2017.1397700 ◽

2017 ◽

Vol 23 (4) ◽

pp. 245-250 ◽

Author(s):

Jing Wang ◽

Xi-Fang Liu ◽

Chong Feng ◽

Quan Bao ◽

Hong-Ran Fu

Keyword(s):

Depressive Disorder ◽

Controlled Study ◽

Efficacy And Safety ◽

Major Depressive ◽

Double Blind ◽

A double-blind, placebo-controlled study of edivoxetine as an adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment

Journal of Affective Disorders ◽

10.1016/j.jad.2014.06.006 ◽

2014 ◽

Vol 167 ◽

pp. 215-223 ◽

Cited By ~ 9

Author(s):

Susan Ball ◽

Mary Anne Dellva ◽

Deborah N. D'Souza ◽

Lauren B. Marangell ◽

James M. Russell ◽

...

Keyword(s):

Depressive Disorder ◽

Selective Serotonin Reuptake Inhibitor ◽

Serotonin Reuptake ◽

Adjunctive Treatment ◽

Controlled Study ◽

Major Depressive ◽

Double Blind ◽

Double Blind Placebo ◽

Inhibitor Treatment

Effect of blue-blocking glasses in major depressive disorder with sleep onset insomnia: A randomized, double-blind, placebo-controlled study

Chronobiology International ◽

10.1080/07420528.2017.1318893 ◽

2017 ◽

Vol 34 (6) ◽

pp. 753-761 ◽

Cited By ~ 12

Author(s):

Yuichi Esaki ◽

Tsuyoshi Kitajima ◽

Ippei Takeuchi ◽

Soji Tsuboi ◽

Osamu Furukawa ◽

...

Keyword(s):

Depressive Disorder ◽

Sleep Onset ◽

Controlled Study ◽

Major Depressive ◽

Double Blind ◽

A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40–120 mg/day) in patients with major depressive disorder

Journal of Drug Assessment ◽

10.3109/21556660.2014.884505 ◽

2014 ◽

Vol 3 (1) ◽

pp. 10-19 ◽

Cited By ~ 21

Author(s):

Carl P. Gommoll ◽

William M. Greenberg ◽

Changzheng Chen

Keyword(s):

Depressive Disorder ◽

Controlled Study ◽

Major Depressive ◽

Double Blind ◽

Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

Pharmacopsychiatry ◽

10.1055/s-2007-991684 ◽

2007 ◽

Vol 40 (05) ◽

Author(s):

M Ebrecht ◽

T Sickmann ◽

M Kungel ◽

C Werner ◽

R Marcus ◽

...

Keyword(s):

Depressive Disorder ◽

Adjunctive Therapy ◽

Controlled Study ◽

Efficacy And Safety ◽

Major Depressive ◽

Double Blind ◽

The efficacy and safety of bupropion sustained-release formulation for the treatment of major depressive disorder: a multi-center, randomized, double-blind, placebo-controlled study in Asian patients

Neuropsychiatric Disease and Treatment ◽

10.2147/ndt.s48158 ◽

2013 ◽

pp. 1273 ◽

Cited By ~ 1

Author(s):

Yoshifumi Kobayashi ◽

Koshino ◽

Won-Myong Bahk ◽

Sakai

Keyword(s):

Depressive Disorder ◽

Controlled Study ◽

Efficacy And Safety ◽

Major Depressive ◽

Double Blind ◽

Release Formulation ◽

Sustained Release Formulation ◽

Double Blind Placebo ◽

Asian Patients

P.8.a.053 A double-blind placebo-controlled study of adjunctive risperidone for treatment-resistant major depressive disorder

European Neuropsychopharmacology ◽

10.1016/s0924-977x(06)70794-5 ◽

2006 ◽

Vol 16 ◽

pp. S562 ◽

Author(s):

G.M. Gharabawi ◽

C.M. Canuso ◽

G.J. Pandina ◽

C.A. Bossie ◽

M. Kujawa ◽

...

Keyword(s):

Depressive Disorder ◽

Controlled Study ◽

Treatment Resistant ◽

Major Depressive ◽

Double Blind ◽